Compare BNC & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNC | SLN |
|---|---|---|
| Founded | N/A | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | 116 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 287.3M | 236.2M |
| IPO Year | N/A | N/A |
| Metric | BNC | SLN |
|---|---|---|
| Price | $3.21 | $6.95 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $42.60 |
| AVG Volume (30 Days) | 233.6K | ★ 398.6K |
| Earning Date | 07-24-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.22 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.39 | $4.19 |
| 52 Week High | $31.62 | $8.40 |
| Indicator | BNC | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 54.94 | 49.52 |
| Support Level | $2.93 | $5.91 |
| Resistance Level | $4.14 | $7.21 |
| Average True Range (ATR) | 0.21 | 0.44 |
| MACD | 0.05 | -0.12 |
| Stochastic Oscillator | 73.75 | 13.95 |
CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.